Influenza vaccination rates are still below public health goals

Early season and end of season flu vaccination coverage estimates
2013-14, 2014-15, 2015-16 and 2016-17 flu seasons

Source: FluVaxView. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
GSK commitment to influenza prevention

Continue to build on Access, Convenience and Education to help increase immunization rates

- **FluLaval Quadrivalent**: 0.5ml dose indication for all eligible persons aged 6 months and older.
- **Fluarix Quadrivalent**: Currently licensed with 0.5 ml dose for all eligible persons aged 3 years and older.
  - sBLA seeking an expanded indication for children 6 months through 35 months of age with a 0.5ml dose was submitted in March 2017

Fluarix and FluLaval are registered trademarks of the GSK group of companies

---

GSK commitment to influenza prevention

Continue to build on Access, Convenience and **Education** to help increase immunization rates

**Supporting medical education in new ways:**
- Independent Medical Education funding model
- GSK has stopped paying HCPs to speak about our vaccines
- Strengthened internal capabilities to drive peer to peer data driven discussions
- GSK medical staff delivering non-promotional educational activities on vaccinology topics
- Partnering with scientific, medical and nonprofit organizations to increase awareness on the value of vaccines
2017-2018 GSK Influenza Vaccines Update

• At GSK, influenza immunization is a high priority
• 35-40 million doses planned for the US *
• All doses will be Quadrivalent Influenza vaccine

*Final quantities will be based on demand & production capabilities
Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

• Do not administer FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT to anyone with known severe allergic reactions (anaphylaxis) to any component of the vaccine, including egg protein, or a life-threatening reaction to previous administration of any influenza vaccine.

• If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

• If FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.

In clinical trials with FLUARIX QUADRIVALENT, the most common injection site adverse reaction in adults was pain. The most common systemic adverse reactions in adults were muscle aches, headache, and fatigue. In children 3 through 17 years of age, injection site adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

• In clinical trials with FLULAVAL QUADRIVALENT, the most common solicited local adverse reaction in adults was pain. The most common solicited systemic adverse reactions in adults were muscle aches, headache, fatigue, and arthralgia. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)

• Vaccination with FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients